Fig. 1.

a Influence of vMIP-II treatment on acute rejection-induced histologic changes: 7 days after transplantation, a reduction in acute rejection with lower glomerular damage, vascular rejection, tubulointerstitial inflammation and tubulointerstitial damage was observed in both dosages. The damage was significantly improved for the high dose treatment group as compared to control for glomerular damage and tubulointerstitial inflammation. Vascular rejection and tubulointerstitial damage were improved as compared to untreated controls, although not significantly. A dose-dependant effect on the reduction of acute rejection-induced changes was noted for the glomerular damage, the tubulointerstitial inflammation and the tubulointerstitial damage (n.s. not significant, p < 0.05). b Untreated allografts show a high rate of adherent and transmigrated leukocytes at the vessel wall as a sign of acute vascular rejection in a preglomerular artery. c In contrast, vMIP-II treatment reduced signs of vascular rejection (endothelialitis), magnification ×400